Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos

Pharmacogenomics

Volumn 12, Issue 5, 2011, Pages 745-756

  Contreras, Alejandra V ^a,b   Monge Cazares, Tulia ^a   Alfaro Ruiz, Luis ^a   Hernandez Morales, Salvador ^a   Miranda Ortiz, Haydee ^a   Carrillo Sanchez, Karol ^a   Jimenez Sanchez, Gerardo ^a   Silva Zolezzi, Irma ^a,c  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

CYP2D6 gene; genetic diversity; Mexicans; resequencing

Indexed keywords

ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; CYP2D7 GENE; DNA POLYMORPHISM; ETHNIC DIFFERENCE; EXON; GENE; GENE CONVERSION; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HISPANIC; HUMAN; MEXICO; PHYLOGENY; POPULATION DYNAMICS; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AND CENTRAL AMERICA;

CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENETIC LINKAGE; GENETIC VARIATION; HAPLOTYPES; HUMANS; INDIANS, NORTH AMERICAN; MEXICO;

EID: 79957633461     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.8     Document Type: Article

References (64)

1. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 {CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J. 5, 6-13 (2005). (Pubitemid 40220611)
2. Weinshilboum R: Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003). (Pubitemid 36159889)
3. Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004). (Pubitemid 38161221)
4. Zanger UM, Fischer J, Raimundo S, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001). (Pubitemid 32953583)
5. Toscano C, Klein K, Blievernicht J, et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *4l allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet. Genomics 16,755-766 (2006). (Pubitemid 44454870)
6. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ: The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45, 889-904 (1989). (Pubitemid 20045231)
7. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS: Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669-682 (1999). (Pubitemid 30011931)
8. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002). (Pubitemid 34223859)
9. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS: Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin. Pharmacol. Ther. 72, 76-89 (2002). (Pubitemid 34833189)
10. Bailliet G, Santos MR, Alfaro EL, et al. Allele and genotype frequencies of metabolic genes in native Americans from Argentina and Paraguay. Mutat. Res. 627, 171-177 (2007). (Pubitemid 46097495)
11. Sosa-Macias M, Elizondo G, Flores-Perez C et al: CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J. Clin. Pharmacol. 46, 527-536 (2006).
12. Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL: Cytochrome P450 enzyme polymorphism frequency in indigenous and native American populations: a systematic review. Community Genet. 11, 141-149 (2008). (Pubitemid 351465617)
13. Qin S, Shen L, Zhang A, et al. Systematic polymorphism analysis of the CYP2D6gene in four different geographical Han populations in Mainland China. Genomics 92, 152-158 (2008).
14. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW: Sequence-based CYP2D6 genotyping in the Korean population. Ther. Drug Momt. 28, 382-387 (2006). (Pubitemid 44314926)
15. Sachse C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60,284-295 (1997). (Pubitemid 27058401)
16. Wan YJ, Poland RE, Han G et al: Analysis of the CYP2D6gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 11, 489-499 (2001). (Pubitemid 32778227)
17. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD: Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 9, 217-228 (1999). (Pubitemid 29359004)
18. MunozS, Vollrath V,VallejosMP, et al. Genetic polymorphisms of CYP2D6, CYPlAl and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8, 343-351 (1998). (Pubitemid 28372328)
19. Sistonen J, SajantilaA, Lao O, CoranderJ, Barbujani G, Fuselli S: CYP2D6worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
20. Lopez M, Guerrero J, Jung-Cook H, Alonso ME: CKP.2D 6" genotype and phenotype determination in a Mexican Mestizo population. Eur. J. Clin. Pharmacol. 61, 749-754(2005). (Pubitemid 41674261)
21. Luo HR, Gaedigk A, Aloumanis V, Wan YJ: Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur. J. Clin. Pharmacol. 61, 797-802 (2005). (Pubitemid 41722129)
22. Mendoza R, Wan YJ, Poland RE, et al. CKPD polymorphism in a Mexican American population. Clin. Pharmacol. Ther. 70,552-560 (2001). (Pubitemid 34008413)
23. Isaza CA, Henao J, Lopez AM, Cacabelos R: Isolation, sequence and genotyping of the drug metabolizer CYP2D6gene in the Colombian population. Methods Find. Exp. Clin. Pharmacol. 22, 695-705 (2000). (Pubitemid 32216825)
24. Agundez JA, Ramirez R, Hernandez M, LlerenaA, BenkezJ: Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. Pharmacogenetics 7, 337-340 (1997). (Pubitemid 27356935)
25. Sans M: Admixture studies in Latin America: from the 20th to the 21st century. Hum. Biol. 72, 155-177(2000). (Pubitemid 30132304)
26. Saenz-Faulhaber M: ElMestizaje en la Integracion de la Pohlacion Colonial, en el Pohlamiento de Mexico. Una Vision Historico-Demogrdfica. Mexico Secretan'a de Gobernacion, Ciudad de Mexico, Mexico (1993).
27. Gerhard P: La Frontera Norte de la Nueva Espana. Universidad Nacional Autonoma de Mexico, Mexico (1996).
28. Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, et al. Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc. Natl Acad. Sci. USA 106, 8611-8616 (2009).
29. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM: Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10, 577-581 (2000).
30. Raimundo S, Toscano C, Klein K et al: A novel intronic mutation, 2988G>A, with high predictivhy for impaired function of cytochrome p450 2D6 in white subjects. Clin. Pharmacol. Ther. 76, 128-138 (2004). (Pubitemid 39013403)
31. Gaedigk A, BhathenaA, Ndjountche L, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 {CYP2D6) gene in African Americans. Pharmacogenomics J. 5, 173-182 (2005). (Pubitemid 40852219)
32. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14, 1-18 (2004). (Pubitemid 38183957)
33. Bodin L, Beaune PH, Loriot MA: Determination of cytochrome P450 2D6 {CYP2D6) gene copy number by real-time quantitative PCR. J. Biomed. Biotechnol. 2005, 248-253 (2005). (Pubitemid 43120932)
34. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003). (Pubitemid 37414228)
35. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001). (Pubitemid 32289743)
36. Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
37. Ng PC, Henikoff S: Sift: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003). (Pubitemid 37442253)
38. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30, 3894-3900 (2002). (Pubitemid 35012462)
39. Barrett JC, Fry B, Mailer J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005). (Pubitemid 40202029)
40. Bandelt HJ, Forster P, Rohl A: Median-joining networks for inferring intraspecific phylogenies. Mol. Biol. Evol. 16, 37-48 (1999). (Pubitemid 29024937)
41. Fuselli S, Dupanloup I, Frigato E, et al. Molecular diversity at the CYP2D6\oc\is in the Mediterranean region. Eur. J. Hum. Genet. 12,916-924 (2004). (Pubitemid 39462125)
42. Zhou Q, Yu XM, Lin HB, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2Cl9znd CYP2D6m Han Chinese. PharmacogenomicsJ. 9, 380-394 (2009).
43. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA: Multiple mutations of the human cytochrome p450HD6 gene {CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265, 17209-17214 (1990).
44. Kruglyak L, Nickerson DA: Variation is the spice of life. Nat. Genet. 27, 234-236 (2001). (Pubitemid 32201838)
45. GaedigkA, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, LeederJS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
46. GaedigkA, Coetsee C: The CYP2D6gene locus in south African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur. J. Clin. Pharmacol. 64, 465-475 (2008).
47. LlerenaA, Dorado P, Ramirez R, et al. CYP2D6genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. DOI:10.1038/tpj.2010.85 (2010) (Epub ahead of print).
48. Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M: Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6gene in Japanese individuals. Drug Metab. Pharmacokinet. 20, 294-299 (2005).
49. Sakuyama K, Sasaki T, Ujne S, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, l4a-b, 18, 27, 36,39, 47-51, 53-55, and 57). Drug Metab. Dispos. 36, 2460-2467 (2008).
50. RamamoorthyA, Flockhart DA, Hosono N, Kubo M, Nakamura Y, Skaar TC: Differential quantification of CYP2D6gene copy number by four different quantitative real-time PCR assays. Pharmacogenet. Genomics 20, 451-454 (2010).
51. Gaedigk A, Fuhr U, Johnson C, Berard LA, Bradford D, LeederJS: CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11, 43-53 (2010).
52. Kramer WE, Walker DL, O'Kane DJ, et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet. Genomics 19, 813-822 (2009).
53. Menoyo A, del Rio E, Baiget M: Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. CellBiochem. Funct. 24, 381-385 (2006). (Pubitemid 44379576)
54. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. Nat. Methods 1, 109-111 (2004).
55. GaedigkA, Isidoro-Garcia M, Pearce RE, et al. Discovery of the nonfunctional CYP2D6*31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur. J. Clin. Pharmacol. 66, 859-864 (2010).
56. Ishiguro A, Kubota T, Sasaki H, Yamada Y, Iga T: Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population. Br. J. Clin. Pharmacol. 55, 414-415 (2003). (Pubitemid 36535374)
57. Ingelman-Sundberg M: Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186-200 (2001). (Pubitemid 34205685)
58. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam. Clin. Pharmacol. 21, 419-426 (2007). (Pubitemid 47084032)
59. Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ: Polymorphisms of CYP2C19 and CYP2D6in Israeli ethnic groups. Am. J. Pharmacogenomics A, 395-401 (2004). (Pubitemid 40052848)
60. SI Chen JM, Cooper DN, Chuzhanova N, Ferec C, Patrinos GP: Gene conversion: mechanisms, evolution and human disease. Nat. Rev. Genet. 8, 762-775 (2007). (Pubitemid 47429210)
61. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M: Inherited amplification of an active gene in the cytochrome p450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. NatlAcad. Sci. USA 90, 11825-11829 (1993). (Pubitemid 24008732)
62. Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6.J. Biol. Chem. 281,7614-7622 (2006). (Pubitemid 43847532)
63. Cairns W, Smith CA, McLaren AW, Wolf CR: Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family J. Biol. Chem. 271, 25269-25276 (1996). (Pubitemid 26337893)
64. Lee SS, Cha EY, Jung HJ, et al. Genetic polymorphism of hepatocyte nuclear factor-4a influences human cytochrome P450 2D6 activity. Hepatology 48, 635-645 (2008).